IR@PKUHSC  > 北京大学第三临床医学院  > 眼科
学科主题临床医学
Efficacy of intra-meibomian gland injection of the anti-VEGF agent bevacizumab for the treatment of meibomian gland dysfunction with lid-margin vascularity
Jiang, Xiaodan; Wang, Yuexin; Lv, Huibin; Liu, Yan; Zhang, Mingzhou; Li, Xuemin
通讯作者Li, Xuemin(1)
关键词meibomian gland dysfunction anti-VEGF lid-margin vascularity
刊名DRUG DESIGN DEVELOPMENT AND THERAPY
2018
DOI10.2147/DDDT.S146556
12页:1269-1279
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Chemistry, Medicinal ; Pharmacology & Pharmacy
研究领域[WOS]Pharmacology & Pharmacy
关键词[WOS]DRY EYE DISEASE ; AQUEOUS-DEFICIENT ; GENE-EXPRESSION ; DIAGNOSIS ; FLUORESCEIN ; POPULATION ; SYMPTOMS ; PATHWAYS ; SURGERY ; LIPIDS
英文摘要

Purpose: To investigate the efficacy of a novel treatment - intra-meibomian gland (MG) injection of the anti-VEGF agent bevacizumnab - for MG dysfunction (MGD) with eyelid-margin vascularity.

Methods: A total of 26 eyes from 13 patients diagnosed with MGD and eyelid-margin vascularity were included in our study. Patients received intra-meibomian gland injections of bevacizumab (150 mu L, 2.5 mg/0.1 mL) at multiple sites with a 29 G needle where telangiectasia was severe. The Ocular Surface Disease Index (OSDI), tear film, tear-breakup time (TBUT), eyelid-margin features, MG features, conjunctiva, and corneal staining were assessed at 1 day before injection and 1 week, 1 month, and 3 months after injection. Blood pressure, best-corrected visual acuity, intraocular pressure, and slit lamp examinations were performed to assure the safety of patients at 1 day before and 1 day, 1 week, 1 month, and 3 months after injection.

Results: Lid-margin vascularity, conjunctival injection, expressed secretion quality, expressivity of the MG, TBUT, corneal staining, and OSDI were significantly improved 1 week, 1 month, and 3 months after injection compared to baseline values. Lid-margin vascularity, conjunctival injection, meibomian gland expressivity, TBUT, and OSDI continued to improve; the greatest improvements were observed at 1 month and sustained for 3 months. Spearman′s correlation analysis indicated that age and sex significantly influenced TBUT improvement. Females and older patients tended to have shorter baseline TBUT that followed a different trend from that of males and younger patients during post injection visits, revealed by subgroup analysis. No local or systemic side effects were observed at follow-up visits.

Conclusion: This study is the first to explore a novel therapy for MGD - intra-MG injection of the anti-VEGF agent bevacizumab - and it demonstrates that the treatment is effective and safe in eliminating eyelid-margin vascularity, improving MG function and relieving clinical signs and symptoms of MGD.

语种英语
WOS记录号WOS:000432400000001
通讯作者邮箱lxmlxm66@sina.com
第一作者单位Peking Univ, Hosp 3, Dept Ophthalmol, 49 Huayuan North Rd, Beijing 100083, Peoples R China
通讯作者单位Peking Univ, Hosp 3, Dept Ophthalmol, 49 Huayuan North Rd, Beijing 100083, Peoples R China
ISSN1177-8881
引用统计
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/141864
专题北京大学第三临床医学院_眼科
作者单位Peking Univ, Hosp 3, Dept Ophthalmol, 49 Huayuan North Rd, Beijing 100083, Peoples R China
推荐引用方式
GB/T 7714
Jiang, Xiaodan,Wang, Yuexin,Lv, Huibin,et al. Efficacy of intra-meibomian gland injection of the anti-VEGF agent bevacizumab for the treatment of meibomian gland dysfunction with lid-margin vascularity[J]. DRUG DESIGN DEVELOPMENT AND THERAPY,2018,12:1269-1279.
APA Jiang, Xiaodan,Wang, Yuexin,Lv, Huibin,Liu, Yan,Zhang, Mingzhou,&Li, Xuemin.(2018).Efficacy of intra-meibomian gland injection of the anti-VEGF agent bevacizumab for the treatment of meibomian gland dysfunction with lid-margin vascularity.DRUG DESIGN DEVELOPMENT AND THERAPY,12,1269-1279.
MLA Jiang, Xiaodan,et al."Efficacy of intra-meibomian gland injection of the anti-VEGF agent bevacizumab for the treatment of meibomian gland dysfunction with lid-margin vascularity".DRUG DESIGN DEVELOPMENT AND THERAPY 12(2018):1269-1279.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Jiang, Xiaodan]的文章
[Wang, Yuexin]的文章
[Lv, Huibin]的文章
百度学术
百度学术中相似的文章
[Jiang, Xiaodan]的文章
[Wang, Yuexin]的文章
[Lv, Huibin]的文章
必应学术
必应学术中相似的文章
[Jiang, Xiaodan]的文章
[Wang, Yuexin]的文章
[Lv, Huibin]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。